Clinical Lymphoma, Myeloma & Leukemia

Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma

Retrieved on: 
Monday, June 5, 2023
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Neutropenia, The New England Journal of Medicine, Arm, Associate professor, FACP, Survival, Aes, OS, Drug, HDT, Clinical Lymphoma, Myeloma & Leukemia, Multimedia, SOC, Doctor of Philosophy, PFS, B-cell lymphoma, MS, MD Anderson Cancer Center, CAR, Progression-free survival, ASCT, Patient, Standard of care, Leukopenia, University, Anemia, EFS, Ageing, SVP, Abstract, Death, Society, Pharmaceutical industry, Axicabtagene ciloleucel, MD

Yescarta is the first treatment in nearly 30 years to demonstrate a significant improvement in survival in this patient population.

Key Points: 
  • Yescarta is the first treatment in nearly 30 years to demonstrate a significant improvement in survival in this patient population.
  • SOC therapy for this patient population has historically been a multi-step process expected to end with stem-cell transplant.
  • Median OS was longer with Yescarta versus SOC (not reached versus 31.1 months, respectively) and 48-month OS estimates were higher with Yescarta (54.6% versus 46.0%, respectively).
  • “Overall survival is the gold standard in cancer treatment and confirms Yescarta’s place as a treatment of curative intent for patients with relapsed/refractory large B-cell lymphoma,” said Frank Neumann, MD, PhD, SVP, Kite’s Global Head of Clinical Development.

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Retrieved on: 
Saturday, December 10, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Lymphoid leukemia, MAA, Food, MD Anderson Cancer Center, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, University, Regulation, Canadian Aviation Regulations, Common Terminology Criteria for Adverse Events, Society, BLA, EMA, NHL, Patient, Cancer, Annual report, Transplant, Clinical Lymphoma, Myeloma & Leukemia, FDA, Disclosure, Division, EST, European Medicines Agency, COVID-19, Marketing, Trial of the century, CAR, Telephone, Safety, Regulation Fair Disclosure, Pharmacokinetics, Biologics license application, Pharmaceutical industry

Enrollment in the Phase 1 clinical study of ADI-001 is currently ongoing to provide additional durability data and further support the recommended Phase 2 dose.

Key Points: 
  • Enrollment in the Phase 1 clinical study of ADI-001 is currently ongoing to provide additional durability data and further support the recommended Phase 2 dose.
  • Upon registration, all participants will receive a confirmation email with a unique passcode to provide access to the webcast event.
  • ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL.
  • Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer.

Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Retrieved on: 
Friday, December 2, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, ACET, Telephone, Safety, Canadian Aviation Regulations, Division, EST, Cancer, MD Anderson Cancer Center, Clinical Lymphoma, Myeloma & Leukemia, Patient, NHL, University, Bio, Pharmaceutical industry

The live webcast of the presentation can be accessed by registering under Presentations & Events in the investors section of the Companys website at https://www.adicetbio.com .

Key Points: 
  • The live webcast of the presentation can be accessed by registering under Presentations & Events in the investors section of the Companys website at https://www.adicetbio.com .
  • Upon registration, all participants will receive a confirmation email with a unique passcode to provide access to the webcast event.
  • To participate via telephone, please join by dialing 1-833-548-0276 (domestic) or 1-646-876-9923 (international) and referencing the conference ID 98173615816.
  • Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer.

Tessa Therapeutics Announces Three Abstracts Highlighting Data from Autologous and Allogeneic Cell Therapy Programs Accepted for Presentation at 64th ASH Annual Meeting and Exposition

Retrieved on: 
Thursday, November 3, 2022
Haematopoietic system, Lymphatic system, Private Securities Litigation Reform Act, DNA, Baylor College of Medicine, Hodgkin lymphoma, Society, Clinical Lymphoma, Myeloma & Leukemia, PRIME, FDA, Marketing, Graft-versus-host disease, Clinical trial, MD Anderson Cancer Center, Hematological Cancer Research Investment and Education Act, Department, Company, Neoplasm, 2021 Essex County Council election, GLOBE, Trial of the century, Ernest, ASH, Plasma, Epstein–Barr virus, CEO, Gene therapy, Cancer, PD, GVHD, Research, European Medicines Agency, Baylor University, Center for Cell and Gene Therapy, Relapse, Holm–Bonferroni method, TT11, Stanford University, Cell, Safety, Therapy, CD30, Risk, Center, CHL, Pharmaceutical industry, Vaccine, Patient, Doctor of Philosophy

TT11X, Tessas allogeneic off-the-shelf cell therapy, is based on Tessas proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform.

Key Points: 
  • TT11X, Tessas allogeneic off-the-shelf cell therapy, is based on Tessas proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform.
  • An abstract highlighting updated data from the ongoing Phase 1/2 study of TT11X (BESTA) in CD30-positive lymphomas will be featured in an oral podium presentation at ASH 2022.
  • We are honored that ASH has accepted three abstracts involving Tessas autologous and allogeneic CD30.CAR-T therapies, including two oral podium presentations, at its prestigious annual meeting, stated Thomas Willemsen, President and CEO of Tessa Therapeutics.
  • Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors.

Caribou Biosciences Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial at the European Hematology Association (EHA) 2022 Hybrid Congress

Retrieved on: 
Friday, June 10, 2022
Caregiver, Steroid, Genome, DLT, Research, Paced Auditory Serial Addition Test, Congress Center, Toxicity, Annual report, RNA, CAR, Security (finance), CRISPR, ET, CRISPR/Cpf1, U.S. Securities and Exchange Commission, Investor, Nasdaq, European Hematology Association, ID, GLOBE, Patient, Division, TRAC, Private Securities Litigation Reform Act, PD-1, Technology, DNA, Risk, Reindeer, EHA, Phenotype, Poster, Clinical trial, CRS, Department, Efficiency, Rachel Haurwitz, University, Clinical Lymphoma, Myeloma & Leukemia, MD Anderson Cancer Center, Lymphatic system, Safety, Pharmaceutical industry, Vaccine

-- Caribou webcast conference call planned for today at 8:00 am ET --

Key Points: 
  • The data are being presented at the European Hematology Association (EHA) 2022 Hybrid Congress , being held in Vienna, Austria, June 9-17, 2022.
  • CB-010 was generally well-tolerated and the adverse events observed are consistent with autologous or allogeneic CAR-T cell therapies.
  • Caribou will host a webcast conference call today to discuss the data presented at EHA on the initial ANTLER data for CB-010.
  • Caribou Biosciences and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.

Caribou Biosciences Announces Webcast Conference Call to Highlight Initial CB-010 ANTLER Phase 1 Data Presentation at EHA on June 10, 2022

Retrieved on: 
Wednesday, June 1, 2022
Genome, Congress Center, Research, CEST, Annual report, RNA, CAR, Security (finance), CRISPR, ET, CRISPR/Cpf1, Investor, U.S. Securities and Exchange Commission, Blood, Nasdaq, ID, GLOBE, Patient, TRAC, Private Securities Litigation Reform Act, PD-1, Technology, DNA, Risk, Reindeer, EHA, Phenotype, Poster, OHC, Clinical trial, Department, Efficiency, Chair, Drug development, Rachel Haurwitz, University, Clinical Lymphoma, Myeloma & Leukemia, MD Anderson Cancer Center, Lymphatic system, Safety, Pharmaceutical industry, Management, Vaccine

The discussion will include longer duration data on the six patients treated at dose level 1 based on a new data cutoff date.

Key Points: 
  • The discussion will include longer duration data on the six patients treated at dose level 1 based on a new data cutoff date.
  • To participate in the conference call, dial 1-844-862-9351 (domestic) or 1-929-517-0932 (international) and reference conference ID #4657536.
  • The archived audio webcast will be available on Caribous website following the call and will be available for 30 days.
  • Caribou plans to issue a data press release at 9:00 am CEST (3:00 am ET) on Friday June 10, 2022.

Sub-analyses of Landmark ZUMA-7 Trial Reinforce Yescarta® CAR T-cell Therapy Superiority Over Standard of Care (SOC) as Initial Treatment for Patients With Relapsed or Refractory Large B-cell Lymphoma (LBCL)

Retrieved on: 
Saturday, June 4, 2022
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Pros, Association, Society, Neoplasm, Food, B-cell lymphoma, Ageing, Standard of care, CAR, ASCO, Annual general meeting, FDA, American Society of Clinical Oncology, Patient, LDH, MS, Risk, Abstract (summary), FACP, Department, SOC, Associate professor, University, Clinical Lymphoma, Myeloma & Leukemia, MD Anderson Cancer Center, EFS, Pharmaceutical industry, Axicabtagene ciloleucel, MD

Yescarta was the first CAR T-cell therapy to be approved by the FDA for the treatment of adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.

Key Points: 
  • Yescarta was the first CAR T-cell therapy to be approved by the FDA for the treatment of adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy.
  • About 30-40% of patients with LBCL will need second-line treatment, as their cancer will either relapse (return) or become refractory (not respond) to initial treatment.
  • Limitations of Use: YESCARTA is not indicated for the treatment of patients with primary central nervous system lymphoma.
  • Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)

Retrieved on: 
Thursday, May 26, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Department, DL2, Regulation Fair Disclosure, ID, Company, Follicular lymphoma, Lymphoid leukemia, Graft-versus-host disease, MD Anderson Cancer Center, Annual general meeting, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Private Securities Litigation Reform Act, Indolent lymphoma, Toxic epidermal necrolysis, Food, U.S. Securities and Exchange Commission, Nasdaq, Kite Pharma, Webcast, Patient, Disclosure, University, Clinical Lymphoma, Myeloma & Leukemia, Risk, IPI, NHL, Bio, Pharmacokinetics, Society, Pneumonia, International Prognostic Index, COVID-19, American Society of Clinical Oncology, Trial of the century, Regulation, FDA, PET/CT, Female, B-cell lymphoma, Safety, CRS, ASCO, CAR, SEC, CR, Cancer, Mantle cell lymphoma, ACET, Annual report, Pharmaceutical industry, Vaccine, Medical imaging, Immunotherapy

The abstract provides a summary of clinical data as of a February 14, 2022, data-cut date.

Key Points: 
  • The abstract provides a summary of clinical data as of a February 14, 2022, data-cut date.
  • We are very pleased to see the continued positive data resulting from our ongoing Phase 1 clinical trial evaluating ADI-001 in relapsed/refractory NHL.
  • There were five patients with large B-cell lymphoma and one with mantle cell lymphoma.
  • Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer.

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

Retrieved on: 
Thursday, May 12, 2022
Regenerative medicine, Lymphoma, Department, Gene therapy, Knowledge, DNA, MD Anderson Cancer Center, Private Securities Litigation Reform Act, Vertex Pharmaceuticals, U.S. Securities and Exchange Commission, Annual report, Cas9, Nasdaq, T-cell lymphoma, University, Form 10-K, Clinical Lymphoma, Myeloma & Leukemia, Coronavirus, Gene editing, Therapy, Degenerative disease, Clinical trial, Congress Center, Lymphatic system, EHA, Hemoglobinopathy, CRISPR, Safety, Technology, Division, CRISPR Therapeutics, CRSP, CD70, Bayer, SEC, Renal cell carcinoma, GLOBE, Pharmaceutical industry, Vaccine, Patient

CTX130 is currently being investigated in two ongoing Phase 1 clinical trials for the treatment of relapsed or refractory renal cell carcinoma and various subtypes of lymphoma, respectively.

Key Points: 
  • CTX130 is currently being investigated in two ongoing Phase 1 clinical trials for the treatment of relapsed or refractory renal cell carcinoma and various subtypes of lymphoma, respectively.
  • CTX130, a wholly-owned program of CRISPR Therapeutics, is a healthy donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 70, or CD70, an antigen expressed on various solid tumors and hematologic malignancies.
  • CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.
  • CRISPR THERAPEUTICS word mark and design logo and CTX130 are trademarks and registered trademarks of CRISPR Therapeutics AG.

Sumitomo Dainippon Pharma Oncology Appoints Jatin J. Shah, M.D. as Chief Medical Officer

Retrieved on: 
Tuesday, February 22, 2022
Division, Internal medicine, Therapy, Sumitomo Dainippon Pharma, Executive, Growth, Clinical Lymphoma, Myeloma & Leukemia, University, Industry, Mechanical engineering, Associate, Private Securities Litigation Reform Act, Yale Physician Associate Program, Ohio State University, Mechanical, Cleveland, Cleveland Clinic, IND, MD Anderson Cancer Center, Cancer, University of Alabama at Birmingham School of Medicine, Advertising, Patient, Translational research, Psychiatry, Research, University college, Department, Pharmaceutical industry, Medical imaging, Oncology

as Executive Vice President, Chief Medical Officer and Global Head of Development.

Key Points: 
  • as Executive Vice President, Chief Medical Officer and Global Head of Development.
  • "Dr. Shah brings significant industry and clinical oncology experience, which is well-aligned with our future growth and success priorities,"said Patricia S. Andrews, Chief Executive Officer, Global Head of Oncology, Sumitomo Dainippon Pharma Oncology (SDP Oncology).
  • Sumitomo Dainippon Pharma Oncology, Inc., is a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. As a global oncology organization with teams in the U.S. and Japan, SDP Oncology is relentlessly committed to advancing purposeful science by transforming new discoveries into meaningful treatments for patients with cancer.
  • Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more than 7,000 employees worldwide.